Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 678 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Serum Collection Clear all

Conditions: Prostate Cancer
Interventions: PROSTVAC-V/F, Nivolumab, Prostatectomy, Biopsy, Tylenol; Biological · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
Interventions: Venipuncture; Diagnostic Test
Lead sponsor: Foundation For Rare Disease Research; Other
Eligibility: 12 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab; Biological · Procedure · Other + 1 more
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
Interventions: Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 12 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lymphoma
Interventions: rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 204
States / cities: Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more

Conditions: Breast Cancer
Interventions: Tumor Sample, Serum Sample; Procedure
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cancer
Interventions: Biospecimen collection; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, CBM588 Capsules, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Biological
Lead sponsor: Osel, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET); Drug · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pregnancy, Heart Diseases
Interventions: echocardiography, blood draw for serum B-type natriuretic peptide; Procedure
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Syracuse, New York

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Interventions: Emavusertib, Pembrolizumab, Stereotactic Radiosurgery, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Biopsy Procedure, Survey Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Myelodysplastic Disorders, Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders
Interventions: FLUDARABINE, CAMPATH 1H, FK50, Stem Cell Collection and Infusion; Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine; Drug · Procedure · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 156
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more

Conditions: Heart Failure, Acute Heart Failure
Interventions: Protocolized diuretic therapy; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: N/A (Observational Study); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more

Conditions: IUGR, Pregnancy
Interventions: Ultrasound, MRI, Blood collection, Neurological Function Assessment, Placental Analysis, Measurement of body fat, Pediatric heart ultrasound; Radiation · Procedure · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diffuse Large B-cell-lymphoma
Interventions: Venetoclax, Rituximab, Ifosfamide, Carboplatin, Etoposide; Drug
Lead sponsor: Molly Gallogly; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Angiography, Biopsy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Positron Emission Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions: miRNAseq analysis, Standard treatment for bone disorder; Procedure · Drug
Lead sponsor: Thomas Nickolas; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: STA-9090, Radiologic imaging, blood draw; Drug · Radiation · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Memphis, Tennessee • Nashville, Tennessee

Conditions: Bladder Cancer
Interventions: Nivolumab, Questionnaires; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: IBD, Crohn Disease, Ulcerative Colitis
Interventions: Breath Test; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Angioedema Biomarker Research Study

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Endothelial Function in Obese Adolescents

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease

CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Longitudinal Study of Intra-Uterine Growth Restriction

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Precision Medicine Approaches to Renal Osteodystrophy

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease